S-hydroxylaminoglutathione

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: S-hydroxylaminoglutathione
• 英文别名: (2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-3-(hydroxyamino)sulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
• 化学式: C₁₀H₁₈N₄O₇S
• 分子量: 338.34
• InChiKey: ZOIIDZWLSVVTGQ-WDSKDSINSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -7.5
• 重原子数：
  22
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  216
• 氢给体数：
  7
• 氢受体数：
  10

文献信息

• [EN] ALKYNE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS<br/>[FR] COMPOSÉS DE TYPE ALCYNE EN TANT QU'INHIBITEURS DE LA S-NITROSOGLUTATHIONE RÉDUCTASE
  申请人：GLENMARK PHARMACEUTICALS SA

  公开号：WO2016055947A1

  公开（公告）日：2016-04-14

  Provided are compounds of formula (Ia) and pharmaceutically acceptable salts thereof, wherein A, B, R 1, R 2, m and n are as defined herein, which are active as inhibitors of S-Nitrosoglutathione reductase (GSNOR). These compounds prevent, inhibit, or suppress the action of GSNOR and are therefore useful in the treatment of GSNOR mediated diseases, disorders, syndromes or conditions such as, e.g., pulmonary hypertension, acute respiratory distress syndrome (ARDS), asthma, bronchospasm, cough, pneumonia, pulmonary fibrosis, interstitial lung diseases, cystic fibrosis and chronic obstructive pulmonary disease (COPD).

  提供的是式(Ia)的化合物及其药学上可接受的盐，其中A、B、R1、R2、m和n如本文所定义，这些化合物作为S-硝基谷胱甘肽还原酶(GSNOR)的抑制剂具有活性。这些化合物可以预防、抑制或抑制GSNOR的作用，因此在治疗GSNOR介导的疾病、疾病、综合征或病症方面具有用处，例如肺动脉高压、急性呼吸窘迫综合征(ARDS)、哮喘、支气管痉挛、咳嗽、肺炎、肺纤维化、间质性肺疾病、囊性纤维化和慢性阻塞性肺疾病(COPD)。
• [EN] THIENOPYRROLE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS<br/>[FR] COMPOSÉS DE THIÉNOPYRROLE UTILISÉS COMME INHIBITEURS DE LA S-NITROSOGLUTATHIONE RÉDUCTASE
  申请人：GLENMARK PHARMACEUTICALS SA

  公开号：WO2016128905A1

  公开（公告）日：2016-08-18

  The present disclosure is directed to compounds of formula (Ib) and pharmaceutically acceptable salts thereof, wherein A, Q, R1, R3, R5 and m are as defined herein, which are active as inhibitors of S-Nitrosoglutathione reductase (GSNOR). These compounds prevent, inhibit, or suppress the action of GSNOR and are therefore useful in the treatment of GSNOR mediated diseases, disorders, syndromes or conditions such as, e.g., pulmonary hypertension, acute respiratory distress syndrome (ARDS), asthma, bronchospasm, cough, pneumonia, pulmonary fibrosis, interstitial lung diseases, cystic fibrosis and chronic obstructive pulmonary disease (COPD).

  本公开涉及化合物及其药用盐的公式(Ib)，其中A、Q、R1、R3、R5和m如本文所定义，这些化合物作为S-亚硝基谷胱甘肽还原酶(GSNOR)的抑制剂具有活性。这些化合物可以预防、抑制或抑制GSNOR的作用，因此在治疗GSNOR介导的疾病、疾病、综合征或疾病方面是有用的，例如肺动脉高压、急性呼吸窘迫综合征(ARDS)、哮喘、支气管痉挛、咳嗽、肺炎、肺纤维化、间质性肺疾病、囊性纤维化和慢性阻塞性肺病(COPD)。
• Kokumi-imparting agent
  申请人：Ajinomoto Co., Inc.

  公开号：EP2327986A1

  公开（公告）日：2011-06-01

  A method for screening for a kokumi-imparting substance, which utilizes calcium receptor activity as an index, a kokumi-imparting agent containing a kokumi-imparting substance obtained by the screening method as an active ingredient, a method for producing food or drink such as food, seasoning, and drink imparted with kokumi, and food or drink imparted with kokumi.

  一种利用钙受体活性作为指标的角美诱导物质筛选方法、一种含有通过筛选方法获得的角美诱导物质作为有效成分的角美诱导剂、一种生产添加角美的食品、调味品和饮料等食品或饮料的方法，以及添加角美的食品或饮料。
• S-nitrosoglutathione (GSNO) and GSNO reductase inhibitors for use in therapy
  申请人：MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

  公开号：US10925858B2

  公开（公告）日：2021-02-23

  The present disclosure provides methods for the treatment of neurological deficits by the administration of GSNO or GSNO reductase inhibitor. Further provided herein are methods of treating autoimmune diseases by administering GSNO or GSNO reductase inhibitor.

  本公开提供了通过施用GSNO或GSNO还原酶抑制剂治疗神经系统缺陷的方法。本文还提供了通过施用 GSNO 或 GSNO 还原酶抑制剂治疗自身免疫性疾病的方法。
• S-NITROSOGLUTATHIONE (GSNO) AND GSNO REDUCTASE INHIBITORS FOR USE IN THERAPY
  申请人：Musc Foundation for Research Development

  公开号：EP3634460A1

  公开（公告）日：2020-04-15